Wednesday, October 13, 2021 2:48:59 PM
Marjac
More
The 3 time points fell within the 12 month limitation period and Epadi brought its action immediately it was able and within that limitation period
“Allowing Epadi to intervene after this case has concluded in this Court for the sole purpose of vacating its judgement would substantially prejudice the defendants as it would nullify the years of work they put into ultimates prevailing in this case “
This was the DC court finding. But this finding as to prejudice flies in the face as to the whole purpose behind Rule 60 applications- and in this case by denying standing ,by virtue of defendants prejudice, the Court has effectively rewarded the devious and dishonest “work” of the defendants (ie the manner in which they presented evidence through their expert and the cropping of the simply crucial table )
The defendants not through years of honest hard work but through dishonesty and an outright fraud on the Court “ ultimately prevailed in this case”
Dishonesty and fraud before a Court can not be ignored and swept aside simply because the dishonest party would loose his ill gotten gains (prejudice)
Before finding prejudice in cases such as this where a serious and immensely financially damaging (7billion in lost shareholder value) has been asserted must vigorously examine the nature of and supporting evidence behind the Rule 60 application to assess their substance and merit to enable it to properly assess the issue of prejudice as to standing . The DC failed to do this
The security blanket behind Rule 60 applications and their purpose was simply thrown away
More to follow
Alm
More
The 3 time points fell within the 12 month limitation period and Epadi brought its action immediately it was able and within that limitation period
“Allowing Epadi to intervene after this case has concluded in this Court for the sole purpose of vacating its judgement would substantially prejudice the defendants as it would nullify the years of work they put into ultimates prevailing in this case “
This was the DC court finding. But this finding as to prejudice flies in the face as to the whole purpose behind Rule 60 applications- and in this case by denying standing ,by virtue of defendants prejudice, the Court has effectively rewarded the devious and dishonest “work” of the defendants (ie the manner in which they presented evidence through their expert and the cropping of the simply crucial table )
The defendants not through years of honest hard work but through dishonesty and an outright fraud on the Court “ ultimately prevailed in this case”
Dishonesty and fraud before a Court can not be ignored and swept aside simply because the dishonest party would loose his ill gotten gains (prejudice)
Before finding prejudice in cases such as this where a serious and immensely financially damaging (7billion in lost shareholder value) has been asserted must vigorously examine the nature of and supporting evidence behind the Rule 60 application to assess their substance and merit to enable it to properly assess the issue of prejudice as to standing . The DC failed to do this
The security blanket behind Rule 60 applications and their purpose was simply thrown away
More to follow
Alm
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
